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ABSTRACT 
 
Background: Immune checkpoint inhibitors targeting programmed cell death (PD) 1 
or its ligand (PD-L1) showed activity in several cancer types.  
 
Methods: We performed  immunohistochemistry for CD3, CD8, CD20, HLA-DR, 
phosphatase and tensin homolog (PTEN), PD-1, and PD-L1 and pyrosequencing for 
assessment of the O6-methylguanine-methyltransferase (MGMT) promoter 
methylation status in 135 glioblastoma specimens (117 initial resection, 18 first local 
recurrence). PD-L1 gene expression was analyzed in 446 cases from Human Cancer 
Genome Atlas.  
 
Results: Diffuse/fibrillary PD-L1 expression of variable extent, with or without 
interspersed epithelioid tumor cells with membranous PD-L1 expression, was 
observed in 103/117 (88.0%) newly diagnosed and 13/18 (72.2%) recurrent 
glioblastoma specimens. Sparse to moderate density of tumor infiltrating 
lymphocytes (TILs) was found in 85/117 (72.6%) specimens (CD3+ 78/117, 66.7%; 
CD8+ 52/117, 44.4%; CD20+ 27/177, 23.1%; PD1+ 34/117, 29.1%). PD1+ TIL 
density correlated positively with CD3+ (p<0.001), CD8+ (p<0.001), CD20+ TIL 
density (p<0.001) and PTEN expression (p=0.035). Enrichment of cases with low 
PD-L1 gene expression levels was observed in the proneural and G-CIMP 
glioblastoma subtypes and of cases with high PD-L1 gene expression in the 
mesenchymal subtype (p = 5.966e-10). No significant difference of PD-L1 expression 
or TIL density between initial and recurrent glioblastoma specimens and no 
correlation of PD-L1 expression or TIL density with patient age or outcome was 
evident.  
 
Conclusion: TILs and PD-L1 expression are detectable in the majority of glioblastoma 
samples, but are not related to outcome. As the target is present, a clinical study with 
specific immune checkpoint inhibitors seems to be warranted in glioblastoma. 
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INTRODUCTION 
Glioblastoma is the most common primary brain tumor of adults and is associated 
with high morbidity and poor median overall survival times of approximately 14 to 17 
months across contemporary studies.1 The current treatment standard for newly 
diagnosed glioblastoma comprises maximal safe resection followed by combined 
radiochemotherapy with temozolomide. So far, experimental treatments with a 
number of biologicals such as anti-invasive (e.g. cilengitide) and anti-angiogenic (e.g. 
cediranib, bevacizumab) agents or inhibitors of specific oncogenic signaling 
pathways (e.g. erlotinib, gefitinib, imatinib, temsirolimus, everolimus, enzastaurin) 
have failed to show overall survival benefits in glioblastoma.2-6 Novel treatment 
concepts based on biological insights are urgently needed to improve patient 
outcomes. 
Glioblastoma has long been recognized as an immunosuppressive neoplasm 
characterized by activation of various immune escape mechanisms including 
upregulation of transforming growth factor-β (TGF-β), indoleamine 2,3 dioxygenase 
(IDO) and programmed death ligand 1 (PD-L1, also known as B7-H1).7-9 Emerging 
evidence suggest differential immunogeneity of molecular glioblastoma subtypes with 
the mesenchymal subtype showing more prominent infiltration by tumor-associated 
lymphocytes (TILs) and expression of immuno-inhibitory molecules.10, 11 Furthermore, 
loss of phosphatase and tensin homolog (PTEN), a recurring molecular alteration in 
glioblastoma, has been postulated to induce PD-L1 expression.9 
Recently, a novel class of immune modulatory antineoplastic agents, so called 
immune check-point inhibitors, showed impressive activity with high response rates 
and durable tumor remissions in several cancer types including melanoma, lung 
cancer, renal cell carcinoma, bladder cancer and head and neck cancer.12, 13 These 
agents act by blocking immunosuppressive receptors that inhibit effector T-cells and 
thus facilitate the anti-tumor immune response. Currently, immune check-point 
inhibitors targeting the programmed death 1 (PD-1) molecule and its ligand PD-L1 
are in advanced clinical development and show compelling activity and favorable 
toxicity profiles across tumor types. PD-1 is a cell surface co-inhibitory receptor that 
is expressed on CD3+/CD8+ T-cells  after activation and limits immune response, 
thus resulting in functionally “exhausted” T cells.14 Importantly, tumoral expression of 
PD-L1 as assessed by immunohistochemistry seems to correlate with response to 
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PD-1/PD-L1 inhibitors and may emerge as a clinically relevant biomarker.13, 15 
Cumulating evidence, mostly from preclinical studies and experimental models, 
indicates a prominent activation of PD-L1 in glioblastoma.9, 16-22 However, systematic 
studies on the expression of PD-L1 in human tissue samples are missing so far. We 
thus set out to characterize PD-L1 expression and its association with other tissue-
based and clinical parameters in a well-annotated retrospective series of human 
glioblastoma samples including matched recurrent tumors to provide a basis for 
clinical trials and translational biomarker research. We additionally investigated PD-
L1 gene expression and its correlation with patient outcome and molecular 
glioblastoma subtypes in the dataset of The Human Cancer Genome Atlas (TCGA). 
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METHODS 
 
Patients and materials 
Vienna retrospective cohort 
We retrospectively identified formalin-fixed and paraffin-embedded (FFPE) tumor 
tissue specimens of 117 adult patients who underwent neurosurgical resection of 
newly diagnosed glioblastoma at the Department of Neurosurgery, Medical University 
of Vienna, between 2006 and 2012 from the Neuro-Biobank of the Institute of 
Neurology, Medical University of Vienna. In 18 patients an additional FFPE tumor 
specimen from the neurosurgical resection of the first local recurrence was available. 
Therefore, a total of 135 specimens (117 newly diagnosed glioblastomas, 18 
matched local recurrences) were used for this study. Histological diagnosis of 
glioblastoma was performed according to the current WHO classification 23. Clinical 
data were extracted by chart review and survival data were retrieved from the 
Austrian Brain Tumor Registry.24, 25 The ethics committee of the Medical University of 
Vienna approved the study (Vote 078/2004). 
The Cancer Genome Atlas (TCGA) data set 
We obtained clinical and GBM gene expression data for a cohort of 446 patients 
available at TCGA (https://tcga-data.nci.nih.gov/tcga/). Expression levels of the PDL-
1 (CD274) gene were derived from the TCGA Agilent custom design platform 
represented by a single probe (A_23_P338479). The clinical data and annotation for 
MGMT promoter methylation and other molecular annotation were taken from 
Brennan et al 2013.26 
 
 
MGMT pyrosequencing 
For determination of the MGMT promoter methylation status, six 10 µm sections of 
newly diagnosed glioblastoma FFPE tissue blocks from the Vienna cohort were cut 
into an Eppendorf tube. DNA isolation was performed using the EpiTect FFPE Lysis 
Kit (Qiagen) and bisulfite modification was performed using the EpiTect Fast FFPE 
Bisulfite Kit (Qiagen). Pyrosequencing analysis was performed on a PyroMark Q24 
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MDx (Qiagen, Germany) system with the therascreen MGMT Pyro Kit (Qiagen) 27. In 
line with previous publications, cases with a mean methylation percentage of <8% 
were regarded as MGMT promoter unmethylated and cases with a mean methylation 
percentage of >8% were regarded as MGMT promoter methylated.27, 28 
 
Immunohistochemical staining 
For immunohistochemical staining, FFPE blocks from the Vienna cohort were cut into 
serial 3 m slices with a microtome. Immunohistochemistry for CD3, CD8, PD-1, 
CD20, HLA-DR, GFAP and PTEN was performed on a Ventana Benchmark Ultra 
immunostaining system (Ventana, Tucson, AZ, USA) and immunohistochemistry for 
PD-L1 was performed using a Dako AutostainerPlusLink immunostaining system 
(Dako, Glostrup, Denmark). In order to facilitate comparison of regional distributions 
of PD-L1 and PTEN expression and TIL infiltration, immunostaining was performed 
on adjacent sections. Antibodies and immunostaining protocols are listed in 
Supplemental Table 1. FFPE tissue blocks of human non-neoplastic lymph nodes 
(TILs) and human placenta (PD-L1) were used as positive controls. For PTEN 
immunostaining, endothelial cells within the tumor tissue served as internal positive 
controls. 
 
Evaluation of immunohistochemistry  
PD-L1 and PTEN expression 
PD-L1 expression was descriptively recorded according to the cellular and 
topographical localization, distribution and intensity of the immunohistochemical 
signal.  
The extent of diffuse/fibrillary PD-L1 and PTEN expression throughout the tumor 
tissue was semiquantitatively assessed according to the following criteria 18, 29: (1) 
no positive tumor areas; (2) expression in less than 25% of non-necrotic tumor area; 
(3) expression in more than 25% and less than 50% of non-necrotic tumor area; (4) 
expression in more than 50% and less than 75% of non-necrotic tumor area; (5) 
expression in more than 75% of non-necrotic tumor area. 
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Presence of epithelioid tumor cells with distinct membranous anti-PD-L1 labelling 
was recorded only if they constituted more than 5% of all tumor cells by 
semiquantitative assessment in order to comply with the cut-off used in previous 
publications.13   
 
TIL density 
Density of CD3+, CD8+, PD1+ and CD20+ TIL subsets was evaluated by overall 
impression at low microscopic magnification (100x). Furthermore, the densities were 
separately scored at higher magnification (200x - 400x) in predefined regions of 
interest, namely: (1) within the glioblastoma tissue; (2) in perivascular regions; and 
(3) in the infiltration zone to the brain parenchyma. Previously published 
semiquantitative evaluation criteria were used to describe TIL infiltration density and 
TIL density was judged to be sparse, moderate or dense.30 The regional distributions 
of the various TIL subset infiltrates and PD-L1-positive and PTEN-positive tumor 
areas were compared on adjacent tissue sections. 
 
Statistical analyses 
Spearman correlation was applied to analyze correlation of two ordinal parameters. 
Chi Square test was used to assess group differences as appropriate. Overall 
survival from diagnosis of glioblastoma to death or last follow up was estimated using 
the Kaplan Meier limit method. The log rank test was used to assess group 
differences. A cox regression model was used to analyze the association of 
continuous variables with survival. A two-tailed significance level of 0.05 was applied. 
Because of the exploratory and hypothesis generating design of the present study, 
no adjustment for multiple testing was applied 31. All statistical analysis was 
performed with statistical package for the social sciences (SPSS) 20.0 software 
(SPSS Inc., Chicago, IL, USA). 
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RESULTS 
Vienna retrospective cohort 
Patients  
The patients’ characteristics including clinical baseline parameters, details on 
administered therapies and results of MGMT promoter methylation status testing are 
listed in Table 1.  
 
PD-L1 expression  
We found prominent PD-L1 staining of variable extent in glioblastoma tissues, while 
the surrounding CNS tissue generally showed no or only very faint and diffuse focal 
labelling of the neuropil and occasional light staining of single and dispersed 
parenchymal cells such as neurons and microglia/macrophages (Figure 1).   
The majority of glioblastoma cases, 103/117 (88.0%) of newly diagnosed and 13/18 
(72.2%) of recurrent cases, showed a prominent diffuse/fibrillary expression pattern 
of variable extent (Figure 2). Diffuse/fibrillary PD-L1 expression was typically found 
in a patchy distribution throughout the tumor tissue without accentuation in the 
perivascular or perinecrotic areas. 
In 44/117 (37.6%) of newly diagnosed and 3/18 (16.7%) of recurrent glioblastomas 
interspersed singular or focally aggregated epithelioid tumor cells with distinct and 
strong membranous PD-L1 immunolabelling was found (Figure 2). In some of these 
tumors in addition to the membranous signal also some faint diffuse or granular 
cytoplasmic staining was observed. Epithelioid PD-L1+ tumor cells were exclusively 
found in cases with diffuse/fibrillary PD-L1 expression. 
Table 2 details the results of semiquantitative evaluation of tumoral PD-L1 
expression. 
In 48/117 (41.0%) specimens with newly diagnosed glioblastoma, surrounding brain 
parenchyma was present and thus evaluable for PD-L1 expression. Among these 
cases, we found some faint anti-PD-L1 staining of neurons in 32/48 (66.7%) cases, 
while in 16/48 (33.3%) specimens no neuronal PD-L1 expression was detected. 
11	
	
TILs and microglia/macrophages 
TIL infiltration of variable density was observed in 85/117 (72.6%) of newly 
diagnosed and 15/18 (83.3%) of recurrent glioblastoma specimens. TIL infiltration 
was in general of sparse to moderate density with TILs mostly located in perivascular 
areas and in zones of tumor invasion into the surrounding brain parenchyma (Figure 
3). TILs were only infrequently found within the tumor tissue and in peri-necrotic 
areas. HLA-DR+ microglia/macrophages were distributed diffusely throughout the 
tumor tissue. Table 3 shows the results of semiquantitative evaluation of the density 
and distribution of CD3+, CD8+, CD20+, PD1+ and HLA-DR+ cells. 
 
PTEN expression 
Anti-PTEN immunostaining distinctly labelled endothelial cells. Diffuse/fibrillary and 
membranous PTEN expression of tumor tissue was detected to a variable extent in a 
patchy pattern through the tumor tissue, without a clear-cut accentuation around 
necrotic areas or vascular structures.   
Among newly diagnosed glioblastoma specimens, the semiquantitative distribution of 
tumoral PTEN expression was as follows: 27/117 (23.1%) cases: negative; 33/117 
(28.2%) cases: less than 25% of tumor tissue positive; 20/117 (17.1%) cases: more 
than 25% and less than 50% of tumor tissue positive; 22/117 (18.8%) cases: more 
than 50% and less than 75% of tumor tissue positive; 15/117 (12.8%) cases: more 
than 75% of tumor tissue positive.  
Among recurrent glioblastoma specimens, the semiquantitative distribution of tumoral 
PTEN expression was as follows: 8/18 (44.4%) cases: negative; 2/18 (11.1%) cases: 
less than 25% of tumor tissue positive; 2/18 (11.1%) cases: more than 25% and less 
than 50% of tumor tissue positive; 4/18 (22.2%) cases: more than 50% and less than 
75% of tumor tissue positive; 2/18 (11.1%) cases: more than 75% of tumor tissue 
positive.  
 
Comparison of the spatial distribution of tissue-based parameters 
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Comparative evaluation of the spatial distribution of the various TIL subsets on 
adjacent sections showed regional overlap of TIL infiltration as CD3+, CD8+ and 
PD1+ TILs were evident in the same areas in consecutive sections (newly 
diagnosed: 51/117, 43.6%; recurrent: 12/18, 66.7%). Infrequently, regional overlap of 
TIL infiltration and PD-L1 expression was observed (newly diagnosed: 18/117, 
15.4%; recurrent: 6/18, 33.3%). No clear-cut accumulation of PD1+ TILs in the 
immediate proximity to PD-L1+ glioblastoma cells or PD-L1+ macrophages was 
observed.  
In most cases, we found no regional overlap of PTEN-negative and PD-L1 positive 
areas on adjacent sections. Only in a minority of cases (newly diagnosed: 31/117, 
26.5%: recurrent: 6/18, 33.3%), we found discordant expression profiles with PD-L1 
positive areas lacking PTEN expression.  
 
Statistical analyses 
Correlation of tissue-based parameters 
PD1+ TIL density correlated positively with CD3+ TIL density (p<0.001; Chi Square), 
CD8+ TIL density (p<0.001; Chi Square), CD20+ TIL density (p<0.001; Chi Square) 
and PTEN expression (p=0.035; Chi Square test), but not with density of HLD-DR+ 
microglia/macrophages (p=0.215; Chi Square test), MGMT promoter methylation 
status (p=0.195; Chi Square test), membranous PD-L1 expression on epithelioid 
tumor cells (p=0.808; Chi Square test) or diffuse/fibrillary PD-L1 expression (p=0.766; 
Chi Square test).  
Diffuse/fibrillary PD-L1 expression was not correlated with CD3+ TIL density 
(p=0.168; Chi Square test), CD8+ TIL density (p=0.068; Chi Square test), CD20+ TIL 
density (p=0.516; Chi Square test) or HLA-DR+ microglia/macrophages (p=0.897; 
Chi Square test), PTEN expression (p=0.232; Chi Square test) or MGMT promoter 
methylation status (p=0.335; Chi Square test). Furthermore, there was no correlation 
between presence of epithelioid tumor cells with membranous PD-L1 expression and 
CD3+ TIL density (p=0.555; Chi Square test), CD8+ TIL density (p=0.380; Chi 
Square test), CD20+ TIL density (p=0.093; Chi Square test), HLA-DR+ 
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microglia/macrophages (p=0.512; Chi square test), PTEN expression (p=0.329; Chi 
Square test) or MGMT promoter methylation status (0.181; Chi square test).  
 
Correlation of tissue-based parameters with clinical characteristics  
There was no correlation between pre-surgical treatment with corticosteroids and 
membranous PD-L1 expression (p=0.283; Chi Square test), diffuse/fibrillary PD-L1 
expression (p=0.513; Chi Square test), density of PD1+ TILs (p=0.534; Chi Square 
test), CD3+ TILs (p=0.889; Chi Square test), CD8+ TILs (p=0.190; Chi Square test), 
CD20+ TILs (p=0.917; Chi Square test) or density of HLA-DR+ 
microglia/macrophages (p=0.542; Chi Square test). Further, no correlation of age (< 
65 years vs. > 65 years) and membranous PD-L1 expression (p=0.612; Chi Square 
test), diffuse/fibrillary PD-L1 expression (p=0.383; Chi Square test), density of PD1+ 
TILs (p=0.945; Chi Square test), density of CD3+ TILs (p=0.418; Chi Square test), 
density of CD8+ TILs (p=0.376; Chi Square test) or density of HLA-DR 
microglia/macrophages (p=0.758; Chi Square test) was evident. However, younger 
patients (< 65 years) presented more frequently with sparse and moderate density of 
CD20+ TILs than patients aged ≥ 65 years at diagnosis of GBM (p=0.043; Chi 
Square test). 
 
Comparison between specimens of first and second resection 
The extent of diffuse/fibrillary PD-L1 expression between newly diagnosed and 
recurrent glioblastoma specimens was not different (p=0.411; Chi Square test; Table 
4). Epithelioid tumor cells with anti-PD-L1 membrane labelling were more common in 
initial tumors (9/18; 50%) than in recurrent tumors (3/18; 16.7%; p=0.034; Chi Square 
test). 
There were no differences between first and second resection for PD1+ TIL density 
(p=0.070; Chi Square test), CD3+ TIL density (p=0.237; Chi Square test), CD8+ TIL 
density (p=0.103; Chi Square test), CD20+ TIL density (p=0.122; Chi Square test), 
HLA-DR+ microglia/macrophage density (p=0.085; Chi Square test) or PTEN 
expression (p=0.289; Chi Square test).  
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Survival analyses  
Young patient age at diagnosis of glioblastoma (< 65 years: 16 months vs. ≥ 65 years 
11 months; p=0.034; log rank test), high KPS (< 70: 4 months vs. > 70: 17 months; 
p<0.001; log rank test), greater extent of resection (subtotal: 12 months vs. total: 18 
months; p=0.003; log rank test) and MGMT promoter hypermethylation (< 8%: 11 
months vs. > 8%: 18 months; p=0.002; log rank test) correlated with overall survival, 
while density of PD1+ TILs (absent: 15 months vs. present 15 months; p=0.981; log 
rank test), presence of diffuse/fibrillary PD-L1 expression (absent: 15 months vs. 
absent 15 months; p=0.921; log rank test) and presence of epithelioid tumor cells 
with membranous PD-L1 expression (< 5%: 15 months vs. > 5% 14 months; 
p=0.724; log rank test), or presence of PD-L1- neurons (negative 15 months vs. 
positive 12 months; p=0.533; log rank test) showed no impact on survival times 
(Figure 4).  
 
TCGA data-set 
Correlation of PD-L1 gene expression with molecular glioblastoma subtypes 
In order to see if there was an association between PD-L1 expression levels and 
known expression subtypes, we classified samples into PD-L1 high/low based on 
median PD-L1 expression levels. The results in Table 5 showed that there is a 
statistically significant difference in the distribution of expression subtypes between 
PD-L1 high and low samples (p-value = 5.966e-10, Pearson's Chi-squared test), with 
a particularly evident enrichment of proneural and G-CIMP expression subtypes in 
the PD-L1 low group, while the mesenchymal expression subtype is over-
represented in the PD-L1 high group. 
Survival analyses 
Survival analysis using Cox proportional hazard (CPH) regression was performed in 
two separate subsets of the data. The first subset comprised a total of 446 patients. 
As the MGMT promoter methylation status was not complete for the 446 patients, it 
was excluded as a covariate, and only age and PD-L1 expression levels were 
included. Both in the univariate and multivariable CPH regression, PD-L1 had no 
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statistically significant association with overall survival of patients (Figure 4H, Table 
6). 
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DISCUSSION 
PD/PD-L1 interactions are now considered central to the immunological control of 
cancer. Here we show prominent expression of PD-L1 by tumor cells in a majority 
human glioblastoma samples. We observed two main staining patterns, which likely 
relate to the particular and heterogeneous microarchitecture of glioblastoma that is 
captured in the widely used descriptive addendum “multiforme”. First, we detected 
clear membranous PD-L1 expression with distinct highlighting of tumor cell surfaces, 
as is seen in epithelial cancers and melanoma.15 This expression pattern was mainly 
found on roundish, non-fibrillar glioblastoma cells with well-delineated cytoplasm and 
cell membranes that have some histological similarities with epithelial cells. Such 
“epithelioid” tumor cells are a well-recognized histological feature of glioblastomas 
and in our series were interspersed within the tumor tissue as single cells or focal 
tumor cell aggregates in 37.6% of newly diagnosed and 16.7% of recurrent 
glioblastoma specimens.23, 32 Second, in some of these tumor cells, we observed in 
addition to the membranous signal also some faint diffuse or granular cytoplasmic 
staining. This may relate to internalized surface PD-L1 molecules, as PD-L1 storage 
and degradation in lysosomes has been described in lymphoma models.33 In many 
cases (88.0% of newly diagnosed and 72.2% of recurrent glioblastoma cases), a 
prominent diffuse/fibrillary PD-L1 immunostaining pattern of variable extent was seen 
throughout the tumor tissue. Due to the intensity of this staining pattern, we consider 
it very likely that this relates to membrane-bound PD-L1 on the delicate and 
intermingled tumor cell processes that form the pathognomic “neurofibrillary matrix” 
of diffuse astrocytic gliomas. However, distinct labelling of tumor cell membranes 
cannot be appreciated in this particular histological presentation due to the limited 
spatial resolution at the light-microscopic level. We did not have the opportunity to 
investigate the subcellular distribution of PD-L1, e.g. by transmission electron 
microscopy with immuno-labelled particles. Notably, we observed no or only very 
faint focal and diffuse staining in the neuropil in tumor-surrounding CNS tissue parts 
with occasional light labeling of parenchymal cell elements. Glial cells (astrocytes, 
microglia, oligodendrocytes) and neurons have been shown to express low or 
undetectable PD-L1 under basal conditions, but are able to up-regulate PD-L1 in 
response to cytokine release in neuroinflammatory processes.34, 35 
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The rate of PD-L1-positive cases in glioblastoma found in our study seems high in 
comparison to other solid tumor types, where approximately 30% of melanoma cases 
and 25 to 36% of non-small cell lung cancer cases have been found to express PD-
L1 by immunohistochemistry.36, 37 Our findings clearly corroborate previous studies in 
experimental models, suggesting a prominent involvement of the PD-1/PD-L1 axis in 
creating an immunosuppressive microenvironment in glioblastoma and taken 
together our data and the experimental evidence provide a strong rationale for 
clinical trials investigating immune check-point inhibitors in this indication. Of 
particular interest in this context are recent reports showing durable therapeutic 
efficacy of immune check-point inhibition in animal models of glial brain tumors.8, 22 
The high prevalence also allows clinical studies without pre-testing the PD-L1 status 
in the tumor tissue, although post hoc correlation of the extent of PD-L1 expression 
with response to treatment may be of interest. Of note, therapeutic efficacy of the 
CTLA4 antibody ipilimumab against melanoma brain metastases has been 
documented, thus showing the feasibility of antibody-mediated immune-checkpoint 
inhibition in intraparenchymal CNS lesions.38, 39 However, further studies will be 
important to investigate in detail the role of the blood-brain/blood-tumor barrier in 
drug penetration and intracerebral efficacy of immune check-point inhibitors. Given 
this uncertainty and the availability of PD1/PD-L1 inhibitors, these may also an option 
for trials in patients with gliomas. 
TIL infiltrates were in general sparse with some concentration of in the perivascular 
areas rather than in the tumor tissue. This finding is well in line with previous 
observations on the distribution of TILs in glioblastoma and suggests that TILs might 
not be able to readily migrate into the immunosuppressive tumor microenviroment 
and arrest in the perivascular.40, 41   
Comparative analysis of newly diagnosed and 18 matched recurrent glioblastomas 
showed no clear up- or down-regulation of PD-L1 and no significant changes in the 
density of PD1+, CD3+, CD8+, or CD20+ TILs over time. Diffuse/fibrillary PD-L1 
expression was common in both newly diagnosed and recurrent specimens. 
Interspersed epitheliod cells with distinct membranous PD-L1 staining were more 
commonly found in newly diagnosed glioblastoma specimens than in recurrent 
cases. However, this finding may be influenced by sampling error and does not 
necessarily indicate a clinically relevant dynamic in PD-L1 expression.  
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We used in our study the non-commercial anti-PD-L1 antibody 5H1, which was kindly 
provided by Dr. Lieping Chen (Yale University). Specificity of this antibody was 
confirmed in a recent publication, while some commercially available antibodies 
failed to show reliable PD-L1 labelling.36 Using the 5H1 antibody, a correlation of 
immunohistochemically detected PD-L1 expression with response to PD1/PD-L1 
inhibition has been shown in metastatic melanoma.13, 15, 42 However, responses to 
PD-1/PD-L1 inhibitors are observed in a significant fraction of patients with PD-L1 
negative tumor samples and the true predictive value of PD-L1 expression is under 
intense investigation in ongoing clinical trials.15, 37 
An association of PD-L1 expression and PTEN loss via PI3K/AKT pathway signaling 
has been shown in several studies in squamous cell cancer, triple-negative breast 
cancer, pancreatic cancer, colorectal cancer, and glioblastoma.9, 18, 20, 43-45 However, 
in our study on human glioblastoma samples we did not find a correlation of PD-L1 
expression and lack of PTEN expression at the protein level and this lack of 
correlation is consistent with a recent study on melanoma.46 PTEN protein 
expression has been shown to poorly correlate with (epi-)genetic PTEN aberrations  
in glioblastoma and further studies may address whether PTEN methylation, PTEN 
mutations, or PTEN deletions correlate with PD-L1 expression in glioblastoma tissue 
samples.29  
Interestingly, we found we found a highly significant association of PD-L1 gene 
expression with molecular glioblastoma subtypes with an enrichment of PD-L1 low 
cases in the proneural and G-CIMP subtypes and PD-L1 high cases in the 
mesenchymal subtype. These results are well in line with some previous studies 
showing evidence for increased immunologic activity in mesenchymal glioblastomas 
and may be explained by an interaction of PD-L1 with signal transducer and activator 
of transcription 3 (STAT3), as STAT3 has been shown to be a major promoter of PD-
L1 expression and to be up-regulated in mesenchymal glioblastomas.11, 47-50 In any 
case, based on our findings clinical studies with PD1/PD-L1 inhibitors need to include 
investigation of differential response patterns across molecular glioblastoma 
subtypes. 
Studies on the prognostic impact of tumoral PD-L1 expression have shown 
inconsistent results across tumor types.20, 51-53 In our series including a total of 563 
glioblastoma cases from two independent cohorts, there was no association of PD-L1 
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expression with patient outcome. In particular, the prognostic impact of neuronal PD-
L1 protein expression recently described in a very small series of 17 glioblastoma 
cases was not corroborated in our series of 117 Viennese cases.19 We appreciate 
that the power of survival analyses in our series is limited by the sample size and the 
retrospective study design and our results surely need confirmation in larger and 
prospectively collected cohorts. However, the known prognostic factors patient age, 
Karnofksy performance status, extent of resection, and MGMT promoter methylation 
status showed the expected separation of prognostic groups and thus validate the 
suitability of our cohort for exploratory survival analyses.  
In conclusion, this analysis shows that PD1 and/or PD-L1 are immunohistochemically 
detectable in a majority of glioblastoma samples, thus suggesting that the 
immunosuppressive PD1/PD-L1 axis is active in glioblastoma. A clinical study with 
specific immune checkpoint inhibitors is warranted in glioblastoma and it remains to 
be seen whether PD-L1 expression patterns or molecular glioblastoma subtypes 
correlate with response to such treatments. 
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FIGURE LEGEND 
 
Figure 1: Low-magnification overview (anti-PD-L1 immunostaining, original 
magnification x 2) showing prominent and patchy PD-L1 expression (arrow 1: 
positive area, arrow 2: negative area) in tumor tissue of a glioblastoma and lack of 
PD-L1 expression in the adjacent brain parenchyma (asterisk). 
 
Figure 2: Diffuse/fibrillary and membraneous PD-L1 expression in glioblastoma.  
A-D (adjacent sections of the same tissue specimen): In glioblastoma areas with 
diffuse/fibrillary histomorphology (A: Hematoxylin and Eosin staining, original 
magnification x 200) and expression of glial fibrillary acidic protein (GFAP; B: anti-
GFAP, original magnification x 200) we found prominent diffuse/fibrillary PD-L1 
expression (C and D: anti-PD-L1; C: original magnification x 200, D: original 
magnification x 400). 
E-H (adjacent sections of the same tissue specien): In glioblastoma areas with 
epithelioid tumor cells (E: Hematoxylin and Eosin staining, original magnification x 
200) and expression of glial fibrillary acidic protein (GFAP; F: anti-GFAP, original 
magnification x 200) we found prominent membranous PD-L1 expression and some 
faint diffuse or granular cytoplasmic staining (G and H: anti-PD-L1; C: original 
magnification x 200, D: original magnification x 400). 
 
Figure 3: A: Dense CD3+ TIL infiltration (magnification x 200) B: PD1+ TILs 
infiltrating glioblastoma (magnification x 400); C: Perivacsular infiltration with CD3+ 
TILs (magnification x 200); D: CD3+ TILs at the infiltration zone (magnification x 200) 
 
Figure 4:  
A- G: Kaplan-Meier curves in the Vienna retrospective cohort. A: Overall survival 
according to age; B: Overall survival according to Karnofsky performance status; C: 
Overall survival according to extent of resection; D: Overall survival according to 
MGMT methylation status; E: Overall survival according to membranous PD-L1 
expression; F: Overall survival according to diffuse/fibrillary PD-L1 expression; G: 
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Overall survival according to PD-L1 expression in neuron. All p-values are according 
to the log rank test; H: Kaplan-Meier curve in the TCGA cohort showing overall 
survival according to PD-L1 gene expression. 
 
